Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia

類似資料

• PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
  著者:: Blom DJ, 等
  出版事項: (2016-05-01)
• Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
  著者:: Sattar, N, 等
  出版事項: (2016)
• An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
  著者:: Hye Duck Choi, 等
  出版事項: (2023-01-01)
• Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
  著者:: Elisa Waldmann, 等
  出版事項: (2022-01-01)
• Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).
  著者:: Elisa Waldmann, 等
  出版事項: (2022-01-01)